Objective
to report the 1-year clinical outcome of half-dose tenecteplase as compared to primary PCI for STEMI in older patients
Study
multicentre randomised trial (2:1 trial)
Population
patients 60 years with STEMI
Endpoints
all-cause mortality at 1 year
Conclusion
the incidence of 1 year all-cause mortality was similar amongst older patients with STEMI treated with half-dose tenecteplase or primary PCI
Sinnaeve et al. Circulation. 2024;150:1151-1153
